Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study (SDCS-PSY)

November 2, 2026 updated by: University Hospital, Toulouse

Superior semicircular canal dehiscence syndrome (SSCD), also known as Minor syndrome, is a rare otoneurological condition characterized by auditory and vestibular symptoms. Emerging evidence suggests a significant psychological burden, including anxiety, depressive symptoms, and suicidal ideation, potentially related to diagnostic delay and chronic symptomatology. However, no structured epidemiological study has systematically assessed quality of life and psychological symptoms in this population.

The aim of this study is to evaluate quality of life and associated psychological symptoms in adults reporting a diagnosis of SSCD using validated self-reported questionnaires in a national cross-sectional survey.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient selection was based on internal communication to members by the French association of patients with Mineur syndrome.

The study was disseminated through specialized consultations.

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Self-reported diagnosis of superior semicircular canal dehiscence syndrome
  • Ability to understand French
  • Non-opposition to participation

Exclusion Criteria:

  • Refusal of data use for research purposes
  • Self-reported cognitive impairment preventing questionnaire completion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
patients with superior semicircular canal dehiscence syndrome

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Overall quality of life score measured using the WHOQOL-BREF questionnaire
Time Frame: The inclusion day
The inclusion day

Secondary Outcome Measures

Outcome Measure
Time Frame
Assessment of the prevalence of depressive symptoms in patients living with CSDS using the average score found on the Beck Depression Inventory (BDI) scale
Time Frame: The inclusion day
The inclusion day
Assessment of the prevalence of anxiety symptoms in patients living with CSDS using the mean score found on the State-Trait Anxiety Inventory (STAI-Y)
Time Frame: The inclusion day
The inclusion day
Assessment of the symptomatic intensity level of each symptom of the SDCS using an average score per item and an overall average score on the Naert questionnaire
Time Frame: The inclusion day
The inclusion day
Assessment of the impact of vestibular symptoms on the functioning of patients living with CSDS using the average score found on the Dizziness Handicap Inventory (DIH) scale
Time Frame: The inclusion day
The inclusion day
Assessment of the level of hopelessness in patients living with SDCS using the average score found on the Beck Hopelessness Scale (BHS)
Time Frame: The inclusion day
The inclusion day
To assess the difference in quality of life between adult patients who underwent surgical management of their CSSD and others using the WHOQOL-BREF score
Time Frame: The inclusion day
The inclusion day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

November 1, 2028

Study Registration Dates

First Submitted

November 2, 2026

First Submitted That Met QC Criteria

November 2, 2026

First Posted (Actual)

November 6, 2026

Study Record Updates

Last Update Posted (Actual)

November 6, 2026

Last Update Submitted That Met QC Criteria

November 2, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • RC31/26/0193

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.